OOIR: Observatory of International Research

Papers

(The TQCC of Expert Opinion on Biological Therapy is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm cli	63
Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males	59
Biosimilars and access to biologic therapy in immune-mediated diseases	55
The endosomal-lysosomal system in ADC design and cancer therapy	53
IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?	40
Microbiota transplantation and administration of live biotherapeutic products for the treatment of dysbiosis-associated diseases	38
Combining VEGF and PD-1/PD-L1 inhibition in advanced hepatocellular carcinoma: clinical trials, real-world evidence, and future directions	35
Antibody drug conjugates for glioblastoma: current progress towards clinical use	35
Aflibercept biosimilars – so near, yet so far	32
Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab	31
Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?	30
Bispecific antibody combination regimens for B-cell non-Hodgkin’s lymphomas	29
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma	29
What’s new in the use of antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) DNA cross-linkers for cancer therapy?	29
Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials	27
Correction	27
A review of bridging clinical studies between different presentations of biological products approved by the United States Food and Drug Administration (US FDA)	27
Signaling new therapeutic opportunities: cytokines in prostate cancer	26
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era	25
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway	23
Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden	22
Long-acting delivery and therapies for neovascular age-related macular degeneration	22
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study	21
TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort	21
Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies	21

Temporal mismatch in allogeneic iPSC therapies: biological risks and implications for clinical translation	21
Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering—an expert perspective	21
Predicting and overcoming poor patient responses to sublingual immunotherapy for allergic diseases	20
Cell population data as predictive biomarkers for biologic therapy response in psoriasis	20
Challenges and considerations in developing trispecific CAR-Ts for B-cell malignancies	20
Treating episodic migraine with precision: the evolving landscape of targeted therapies driven by insights in disease biology	20
Non-canonical function of erythropoietin and downstream effects of erythropoietin-mediated signaling beyond its role in erythropoiesis	20
Unmet needs in cervical cancer – can biological therapies plug the gap?	19
New biological agents in systemic lupus erythematosus	19
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)	19
Correction	19
An evaluation of guselkumab for the treatment of ulcerative colitis	18
Correction	18
ARIAN protocol: a phase III study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancer	17
Reduced doses of biological therapies in psoriasis: a new potentially “sustainable” frontier of psoriasis treatment	17
What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?	17
Relapses in giant cell arteritis: challenges after discontinuation of targeted therapies	17
Dynamics of biological markets with multiple biosimilar competitors in the United States	16
Beyond innovation: why rare disease gene therapy needs a reset	16
Locked and loaded: engineering and arming oncolytic adenoviruses to enhance anti-tumor immune responses	16
Strategies for extending the half-life of biotherapeutics: successes and complications	16
With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?	15
Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective	15
The nail in psoriatic arthritis: new insights into prognosis and treatment	15
Biologic therapy for chronic spontaneous urticaria in pediatrics and adolescents: current landscape, challenges, and future perspectives	15
Emerging strategies for the prevention and management of chronic graft-versus-host disease	15
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy	14
Review of emerging biological therapies for recurrent and advanced metastatic cervical cancer	14
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities	14
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies	14
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma	14
Management of proctitis in ulcerative colitis and the place of biological therapies	14
The management of axial spondyloarthritis with cutting-edge therapies: advancements and innovations	13
The status and preparation for the next decade of biosimilars in the Middle Eastern and North African region	13
Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors	13
Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19	13
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward	13
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children	13
Comparative efficacy, safety and immunogenicity of biosimilars and their reference biologic drugs in ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials	13
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer’s disease	13
Tarlatamab for small-cell lung cancer	12
Optimizing withdrawal strategies for anti-TNF-α therapies in rheumatoid arthritis	12
Emerging peptide-based technology for biofilm control	12
Personalizing immunotherapy for renal cell carcinoma: how far have we come?	12
Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer	12
Evaluation of biological treatment in pediatric patients with familial Mediterranean fever: a retrospective study of 832 patients	12
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project	12
Recent developments and future clinical prospects of polyclonal antibody therapies	11
An evaluation of pozelimab for the treatment of CHAPLE disease	11
Efficacy, safety, and ARIA risk of anti–β-amyloid antibodies in early Alzheimer’s disease: a systematic review, meta-analysis, and meta-regression	11

Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan	11
Talquetamab for the treatment of relapsed/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence	11
Microbiome therapeutics for the treatment of recurrent Clostridioides difficile infection	11
Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations	11
Correction	11
An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis	11
Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma	11
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives	11
A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects	11
Tremelimumab for the treatment of hepatocellular carcinoma	11
Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspective	11
The role of monoclonal antibodies in the treatment of lupus nephritis	10
Biosimilars in osteoporosis treatment: focus on denosumab	10
Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency)	10
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents	10
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era	10
Belimumab patient profile in Spain: evolution during the last decade and future directions	10
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study	10
Clinical management and innovation in fracture non-union	10
Non-traditional approaches for control of antibiotic resistance	10
Long-term effectiveness and safety of ustekinumab in patients with Crohn’s disease: real-world evidence	9
Targeting virus-specific CD8+ T cells for treatment of chronic viral hepatitis: from bench to bedside	9
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study	9
An evaluation of mepolizumab as an add-on maintenance treatment for severe eosinophilic asthma	9
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn’s disease, and chronic plaque psoriasis	9
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics	9
Shared challenges in the management of difficult-to-treat chronic inflammatory diseases: expert perspectives	8
Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials	8
Sargramostim in acute radiation syndrome	8
Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial	8
An evaluation of nadofaragene firadenovec-vncg for the treatment of high-risk BCG-unresponsive non-muscle-invasive bladder cancer	8
Biologics in rectal cancer	8
Correction	8
Antibody therapeutics for epithelial ovarian cancer	8
Breaking immune exclusion in cold tumors via TGF-β pathway inhibition	8
Epcoritamab in B-cell malignancies: current status and prospects	8
An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis	8
An overview of site-specific methods for achieving antibody drug conjugates with homogenous drug to antibody ratio	8
The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target	8
X-linked myotubular myopathy: an untreated treatable disease	8
Comparative overview of biosimilar regulatory frameworks and international harmonization trends	8
Current status and future potential of CD123-based targeted therapies for acute leukemia	8
Perspectives on the use of biological therapies for the treatment of asthma in low-middle income countries	8
Perspectives on the de-escalation of anti-CD20 monoclonal antibodies in patients with multiple sclerosis	7
Improving health literacy and patient-directed knowledge of fecal microbiota transplantation (FMT) through analysis of readability: a cross-sectional infodemiology study	7
Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomiz	7
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?	7
Monoclonal antibodies for dyslipidemia in adults: a focus on vulnerable patients groups	7
Expression of Concern:	7
Ravulizumab for the treatment of myasthenia gravis	7
Ex vivo gene therapy for lysosomal storage disorders: future perspectives	7
The future of interleukin gene therapy in head and neck cancers	7
Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting	7
Second-line strategies after anti-TNF failure in chronically active, moderate-to-severe ulcerative colitis: a retrospective, multicentre cohort study	7
The future of cellular therapy for the treatment of renal cell carcinoma	7
Belantamab mafodotin in multiple myeloma	7
CAR T cells for solid tumors – developments to watch in 2023	7
Stem cell therapy for acute myocardial infarction: Mesenchymal Stem Cells and induced Pluripotent Stem Cells	7
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa	7
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-atto	7
Advanced therapies targeting IL-23: clinical outcomes in ulcerative colitis	7
Monoclonal antibodies against pediatric ulcerative colitis: a review of clinical progress	7
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk	7
Monoclonal antibodies in the management of hereditary angioedema	7
Biologic therapy through caregivers’ eyes: insights from a multicenter pediatric rheumatology survey	7
Advances in the management of giant cell arteritis–aortitis: biologic therapies and beyond - a narrative review	7
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study	7
“Full-naïve” patients: the impact of previous methotrexate, cyclosporine, and acitretin on first-line biologics response in the treatment of moderate-to-severe psoriasis – a monocentric retrospective	7
Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease	7